{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.9","upperLimit":"87.7","value":"80.8"},{"groupId":"OG001","lowerLimit":"158","upperLimit":"210","value":"184"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"description":"Oral volume of distribution (V/F) of dabrafenib and trametinib were assessed using a population approach. Oral volume of distribution (V/F) is defined as the apparent volume of distribution in the central compartment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"OG000","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received Trametinib 1 mg or 2 mg tablets QD.","id":"OG001","title":"Part C: Trametinib"}],"paramType":"MEAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48","title":"Part C: Oral Volume of Distribution (V/F) of Dabrafenib and Trametinib","type":"SECONDARY","unitOfMeasure":"Liters (L)"}